Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor
Anne Bertling(University Hospital Münster), Beate E. Kehrel(University Hospital Münster), Johannes Waltenberger(University of Münster), Reinhard Kelsch(University Hospital Münster), Lisa Schüngel(University Hospital Münster), Walter Sibrowski, Anke C. Fender(West German Heart and Vascular Center Essen), K. Mergemeier(University Hospital Münster), Joseph A. Jakubowski(Indiana Biosciences Research Institute), G Geissler(Klinik und Poliklinik für Psychotherapie und Psychosomatik), M. Rumpf(University Hospital Münster)
Cited by 32
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities
|Journal of Biological Chemistry|1996|845
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617